Bone Marrow Transplantation

Article	Citations
Trading tissues for freedom: incentivizing stem cell and solid organ donation in the incarcerated population	277
Measurable residual disease for secondary acute myeloid leukemia prior to allogeneic hematopoietic cell transplantation: does it make a difference?	171
Prognostic impact of HLA supertype mismatch in single-unit cord blood transplantation	113
Cardiorespiratory fitness and physical performance after childhood hematopoietic stem cell transplantation: a systematic review and meta-analysis	65
Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy	57
Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Result	53
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Poster Session (P613-P616)	52
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards	52
Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency	48
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Oral Session (NO001 – NO006)	46
When is a chimaera not a chimaera?	45
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Statistical Symposium - Poster Session (P611-P612)	43
Mild clinical course of SARS-coronavirus-2 infection early posttransplant in patients with adoptively transferred antibody response	42
Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation	42
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: statistical symposium-poster session (P188–P189)	39
Risk factors for chronic kidney disease following acute kidney injury in pediatric allogeneic hematopoietic cell transplantation	38
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Oral Session (NO001 – NO010)	36
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group - Oral Session (O170-O171)	35
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany	33
Pre-engraftment Cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation and its impact on engraftment	33
Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation	33
Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic stem cell transplantation	32
Prognostic impact of chromosomal changes at relapse after allogeneic hematopoietic cell transplantation for acute myeloid leukemia or myelodysplastic syndrome	31
Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation	31
Risk factors and long-term outcomes for human herpesvirus 6 encephalitis in the early period after allogeneic stem cell transplantation	29

Standardized translations of the Lee Chronic GvHD Symptom Scale to 12 European languages: an EU COST Action cGvHD Eurograft project	28
Alemtuzumab-based conditioning regimen before hematopoietic stem cell transplantation in patients with short telomere syndromes: a retrospective study of the SFGM-TC	28
Challenges and successes in cellular therapies and CAR-T: insights from the 50th EBMT annual meeting	28
Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia	28
Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis	27
HLA-identical related hematopoietic stem cell transplantation in severe sickle cell disease: age is not a barrier to successful outcome	26
Diversity, equity, and inclusion in transfusion medicine, blood donation, and blood and bone marrow transplantation: language matters	25
HLA-E expression constitutes a novel determinant for ALL disease monitoring following hematopoietic stem cell transplantation	24
Efficacy of artesunate for treatment of cytomegalovirus reactivation post allogeneic haematopoietic stem cell transplants	23
Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of curre	23
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey)	23
Exploration of efficacy and safety of combined therapy of basiliximab with ruxolitinib for grade 3–4 steroid-refractory acute graft-versus-host disease: a registered clinical trial (NCT05021276)	22
‘Save the day with a Stem Cell Rescue’: Use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy	22
Graft engineering: how long can you wait, how low can you go, and pandemic readiness	21
On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone	21
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P183-P186)	20
Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCT	20
Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation	19
Validation of the CIBMTR scoring system in predicting early relapse of multiple myeloma after autologous hematopoietic cell transplant	19
Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study	19
The impact of graft cell source on bloodstream infection in the first 100 days after allogeneic hematopoietic cell transplantation	19
Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matche	19
Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in childre	19
Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study	19
The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation	18
OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)	18
Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies	18
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party	17
Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors – first 10 years of prospective donor follow-up of Swiss donors	17
Fertility outcomes in patients desiring conception following autologous stem cell transplantation for hodgkin lymphoma using LACE conditioning	17
Abnormal body composition related to the early clinical adverse outcome after HSCT	17
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial	17
Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11	16
Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor	16
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China	16
CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic	16
Climate change in wine and haematology	16
A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection	16
Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children	16
Patient-generated strategies for strengthening adherence to multiple medication regimens after allogeneic stem cell transplantation: a qualitative study	16
Liver stiffness measurements predict Sinusoidal Obstructive Syndrome after hematopoietic stem cell transplantation	16
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants	16
CD14 positive cells accelerate hematopoietic stem cell engraftment	16
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation	15
The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation	15
HLA-matched HSCT using targeted busulfan-based conditioning in children with primary hemophagocytic lymphohistiocytosis	15
Infusion of haploidentical HSCs combined with allogenic MSCs for the treatment of ALL patients	15
Vampires, blood and wine	15
Analysis of survival outcomes in haematopoietic cell transplant studies: Pitfalls and solutions	15
Health-related quality of life in pediatric patients with β-thalassemia major after hematopoietic stem cell transplantation	14

Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain/amplification and remission status: a nationwide registration study in	14
Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantation	14
Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients	14
NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models	14
Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study	13
Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD	13
Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch	13
Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes	13
Infective hyperammonaemic encephalopathy after allogeneic stem cell transplant	13
Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression	13
Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT	13
Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective	13
Myths in wine and medicine	13
Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies	13
The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma	13
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM	13
Cancers after hematopoietic cell transplantation for aplastic anemia—the importance of persistence	13
Viral infections and risk, in Wine and Medicine	13
Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia	12
Lower incidence of acute graft-versus-host disease with post-transplantation cyclophosphamide compared to anti-thymocyte globulin in higher-risk myelodysplastic syndrome	12
Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era	12
Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myelom	12
Chronic graft-versus-host disease exacerbation after SARS-CoV-2 vaccination	12
Donor/recipient Rh-mismatched allogeneic hematopoietic stem cell transplantation: transfusion strategy and allo-immunization to red blood cell antigens	12
Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status	12
Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan	12
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy	12
Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study	12
Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence	12
Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT	11
T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection	11
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Organising committee	11
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Poster Session (P758-P762)	11
Long-term pulmonary function tests and complications following allogeneic stem cell transplantation	11
FLT3-ITDos and FLT3-ITDon’ts: navigating maintenance therapy in FLT3-ITD-positive acute myeloid leukemia following stem cell transplantation	11
Novel conditioning regimen for upfront haploidentical hematopoietic cell transplantation in children with severe aplastic anemia and donor-specific anti-HLA antibodies	11
Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease	11
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards	11
Low diversity of gut microbiota in the early phase of post-bone marrow transplantation increases the risk of chronic graft-versus-host disease	11
Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia—a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Socie	11
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P725-P741)	11
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Statistical Symposium - Poster Session (P754-P757)	11
Donor-specific HLA antibodies associate with chronic graft-versus-host disease in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide	11
A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years o	11
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma	11
Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL	11
Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia	11
Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib	10
Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation	10
Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Jo	10
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients	10
Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial	10
Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study	10
Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients	10
Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant	10
Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation	10
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Part	10
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma	10
AI in wine and haematology	10
Grading bloodstream infection risk using citrulline as a biomarker of intestinal mucositis in patients receiving intensive therapy	10
Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial	10
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma	10
Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin	10
A non-interventional study of microcirculation dynamics in allogeneic hematopoietic cell transplantation survivors compared to controls: evidence of impaired microvascular response regardless of conve	10
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission	10
Herpes simplex virus reactivation among hematopoietic stem cell transplant recipients: re-evaluating acyclovir dosage	10
Randomized phase 2 study of digital life coaching during transplantation for myeloma	10
Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients – targeting the target antigen	10
Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopo	10
Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Wo	9
Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study	9
Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors	9
Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen	9
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Wo	9
Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant	9
Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis	9
Beyond fludarabine: pentostatin plus cyclophosphamide are a well-tolerated alternative in reduced intensity conditioning	9
T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease	9
Dynamics of recent thymic emigrants in pediatric recipients of allogeneic hematopoetic stem cell transplantation	9
Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15	9

The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O008)	9
Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation	9
Cellular therapy processing laboratory: a workforce hiring nightmare	9
Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogene	9
Cancer incidence in healthy Swedish peripheral blood stem cell donors	9
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)	9
Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion—multicenter prospective observati	9
Evaluation of prognostic scores for respiratory syncytial virus infection in a French multicentre cohort of allogeneic haematopoietic stem cell transplantation recipients	9
Autoimmune cytopenias following pediatric hematopoietic cell transplant	9
Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy	9
Diversity in wine and haematology	9
Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease	9
Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pedia	9
Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy	9
Successful use of narsoplimab to treat allogeneic transplant-associated thrombotic microangiopathy while maintaining sirolimus	9
Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT	9
In memory of Kristin Page 1974–2024	8
Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peri	8
Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy	8
Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience	8
Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score	8
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey	8
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse	8
Correction to: The coming of age of the pediatric EBMT criteria	8
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma	8
Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients	8
Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractor	8
Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning	8
Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion	8
Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome	8
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial	8
Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation	8
The effect of danger-associated molecular patterns on survival in acute graft versus host disease	8
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation	8
Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey	8
Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation	8
Incremental donor lymphocyte infusion to treat mixed chimerism after allogeneic stem cell transplantation in children with non-malignant diseases	8
Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey	8
Gender equality in wine and medicine	7
Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study	7
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas	7
Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on b	7
Correction: Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians	7
Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)	7
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study	7
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P762-P770)	7
Fecal microbiota transplantation for the treatment of steroid-refractory, intestinal, graft-versus-host disease in a pediatric patient	7
Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T	7
Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantati	7
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis	7
Correction: An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT	7
Correction to: Ex vivo generated human T-lymphoid progenitors as a tool to accelerate immune reconstitution after partially HLA compatible hematopoietic stem cell transplantation or after gene therapy	7
Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecuti	7
Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study	7
Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia	7
Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation	7
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards	7
Impact of graft CD34+ cell counts on hematological recovery in patients receiving post-transplant cyclophosphamide prophylaxis	7
Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia	7
Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis	7
Correction: Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients	7
A systematic review and meta-analysis of HHV-6 and mortality after hematopoietic cell transplant	7
High level serum IL-6 predicts occurrence of TA-TMA	7
Correction: The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee—Poster Session (P716-P724)	7
Wine without alcohol: medicine without doctors!	7
Correction to: A SAS macro for estimating direct adjusted survival functions for time-to-event data with or without left truncation	7
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Session (O009-O154)	7
Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders	7
CAR-T cell therapy embarks on autoimmune disease	7
Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity	7
High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell tr	6
Efficacy of eculizumab in transplantation-associated thrombotic microangiopathy: results of the French nationwide study on behalf of the SFGM-TC and the CNR-MAT	6
Outpatient transplantation in the COVID-19 era: a single-center Latin American experience	6
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant	6
The first steps towards a diverse and inclusive EBMT: a position paper	6
Predictors and significance of kidney dysfunction in patients with chronic graft-versus-host disease	6
Predictors and outcomes of flares in chronic graft-versus-host disease	6
Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study	6
Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (E	6
The impact of cult behavior on haematopoietic cell transplant practices: believers and non-believers	6
Impact of hematopoietic cell transplant frailty scale on transplant outcome in adults	6
Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study	6
Venetoclax-based salvage for management of relapsed acute leukaemia after allogeneic haematopoetic stem cell transplant: durable remissions only seen following consolidation with donor lymphocyte infu	6
Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells	6
Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Société Francophone de Greffe de	6
The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001	6
Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Assoc	6
High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant	6
Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas	6
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experie	6
Impact of patient and clinical characteristics on cognitive changes after allogeneic hematopoietic stem cell transplantation	6
Limited utility of chimeric antigen receptor (CAR) T-cell retreatment: experience with a human anti-CD19 CAR	6
Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients	6
Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem c	6
Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia	6